Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Reductions in mortality should not be the only marker of success
| The first 150 words of the full text of this article appear below. |
Many countries initiated national screening programmes for breast cancer after the results of the Swedish two counties trial were published in 1985.1 This trial, which took place in Kopparberg and Östergötland, found that mortality from breast cancer fell by 31% after seven years' follow up of women who had been aged 40-74 at the beginning of the trial. These findings confirmed the results of an earlier trial by Shapiro et al.2 Finland and Sweden started their programmes in 1986, the United Kingdom in 1988, and the Netherlands in 1989. Those in charge of health policy in these countries now want evidence that these programmes are achieving their goals.
Can the results of randomised controlled trials be generalised, and can
the impact be maintained when findings are put into practice? The
crucial point of this process is the setting of the goal, which
for screening with mammography is usually a reduction in mortality from
breast